Leishmaniasis, Cutaneous Clinical Trial
Official title:
Miltefosine Combined With Intralesional Pentamidine for Leishmania Braziliensis Cutaneous Leishmaniasis in Bolivia
Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5). Efficacy and tolerance parameters were assessed. Efficacy was assessed at 1, 3, and 6 months post therapy. Tolerance was assessed on each day therapy was administered. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01140191 -
Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis
|
Phase 2 | |
| Completed |
NCT03999970 -
A Clinical Study to Develop an Uninfected Sand Fly Biting Protocol
|
N/A | |
| Completed |
NCT00111553 -
Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis
|
Phase 1 | |
| Recruiting |
NCT03762070 -
Evaluation of a Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in Peru
|
||
| Completed |
NCT02894008 -
A Study of a New Leishmania Vaccine Candidate ChAd63-KH
|
Phase 2 | |
| Completed |
NCT03303898 -
ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE -
|
N/A | |
| Recruiting |
NCT05094908 -
Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis
|
Phase 1 | |
| Completed |
NCT01083576 -
Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama
|
Phase 2 | |
| Withdrawn |
NCT04072874 -
Evaluation of the Safety and Clinical Activity of Curaleish in the Topical Treatment of Cutaneous Leishmaniasis.
|
Phase 1/Phase 2 | |
| Completed |
NCT01032382 -
Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)
|
Phase 2 | |
| Completed |
NCT00480883 -
Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol
|
N/A | |
| Recruiting |
NCT05708625 -
Intralesional Voriconazole, or Intralesional Cryotherapy, or Oral Doxycycline in the Treatment of Cutaneous Leishmaniasis
|
Phase 3 | |
| Completed |
NCT04841239 -
Development of Topical Herbal Formulations for Treatment of Cutaneous Leishmaniasis
|
N/A | |
| Completed |
NCT00469495 -
Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis
|
N/A | |
| Completed |
NCT03294161 -
Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis
|
Phase 2 | |
| Completed |
NCT04888130 -
Investigation of an Outbreak Situation of Cutaneous Leishmaniasis Among Military Personnel in French Guiana (CEFELEISH)
|
||
| Completed |
NCT03969134 -
A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL
|
Phase 2 | |
| Completed |
NCT03096457 -
Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia
|
Phase 2/Phase 3 | |
| No longer available |
NCT00508963 -
Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis
|
||
| No longer available |
NCT01641796 -
Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis
|